Zacks Small Cap Research on MSN
DYAI: Purchase Orders Rolling In
DYAI READ THE FULL DYAI RESEARCH REPORT Dyadic Applied BioSolutions, Inc. (NASDAQ:DYAI) announced third quarter 2025 results on November 12th, 2025, and held a conference call to discuss them after ...
Through a $650,000 USDA Grant Yi Li will study the unintended consequences of multiplex genome editing and how many ...
Given the success of the Research Topic ‘Diversity and Molecular Diagnostics of Fungi and Oomycetes in Plants’ Volume I and the rapidly evolving subject ...
In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global biotechnology ...
CRISPR-Cas9 is a promising approach for obesity therapy, targeting key genes involved in appetite regulation, metabolism, and ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...
ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered, animal-free proteins and enzymes for diverse ...
Stocktwits on MSN
Retail Bulls Call CRISPR ‘Criminally Undervalued’ After Gene-Editing Breakthrough Cuts Cholesterol By 70%
Phase 1 data showed CRISPR’s one-time treatment, CTX310, produced sharp, dose-dependent reductions in triglycerides and LDL ...
Life sciences revolve around many living forms such as humans, plants, animals, and microorganisms. The discoveries made ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback